Showing results (1-10 of 40) with videos related to
Sort By:
Pageof 4
Oncoimmunology|November 19, 2013
The Janus face of cyclophosphamide: A sterile inflammatory response that potentiates cancer immunotherapyGiovanna Ziccheddu, Enrico Proietti, Federica MoschellaBiomed Research International|November 7, 2013
Immune monitoring in cancer vaccine clinical trials: critical issues of functional flow cytometry-based assaysIole Macchia, Francesca Urbani, Enrico ProiettiAnnals of the New York Academy of Sciences|June 15, 2007
IFN-alpha and novel strategies of combination therapy for cancerLaura Bracci, Enrico Proietti, Filippo BelardelliMolecular Oncology|December 20, 2011
Exploitation of the propulsive force of chemotherapy for improving the response to cancer immunotherapyEnrico Proietti, Federica Moschella, Imerio Capone, et al.Cytokine & Growth Factor Reviews|January 13, 2015
Twenty-five years of type I interferon-based treatment: a critical analysis of its therapeutic useGuido Antonelli, Carolina Scagnolari, Federica Moschella, et al.Annals of the New York Academy of Sciences|June 12, 2010
Combination strategies for enhancing the efficacy of immunotherapy in cancer patientsFederica Moschella, Enrico Proietti, Imerio Capone, et al.Cytokine & Growth Factor Reviews|July 12, 2017
The added value of type I interferons to cytotoxic treatments of cancerLaura Bracci, Antonella Sistigu, Enrico Proietti, et al.Cytokine & Growth Factor Reviews|March 20, 2002
Interferon-alpha in tumor immunity and immunotherapyFilippo Belardelli, Maria Ferrantini, Enrico Proietti, et al.Expert Review of Vaccines|April 9, 2008
Type I interferons as vaccine adjuvants against infectious diseases and cancerLaura Bracci, Valentina La Sorsa, Filippo Belardelli, et al.Expert Review of Vaccines|April 22, 2011
IFN-α as a vaccine adjuvant: recent insights into the mechanisms and perspectives for its clinical usePaola Rizza, Imerio Capone, Franca Moretti, et al.Pageof 4